Managing Candida auris fungemias: the results of a prospective and international study

Faculty Medicine Year: 2025
Type of Publication: ZU Hosted Pages:
Authors:
Journal: Antimicrob Agents Chemother . American Society for Microbiology (ASM) Volume:
Keywords : Managing Candida auris fungemias: , results , , prospective    
Abstract:
Candida auris causes hospital outbreaks and life-threatening infections, is recognized as a global health threat, and was designated a priority pathogen by the World Health Organization (WHO). Since the data on C. auris fungemias are quite scarce and limited to small retrospective case series, this international study aimed to prospectively assess patient characteristics, outcomes, and therapeutic approaches. The study, conducted through the Infectious Diseases-International Research Initiative (ID-IRI) platform, involved 34 referral centers. Patients with C. auris candidemia were prospectively enrolled between 15 April 2024 and 15 October 2024. Data on demographics, clinical and laboratory findings, treatment details, and 30-day mortality outcomes were collected. Mortality risk factors were analyzed using univariate tests and stepwise multiple binary logistic regression. The study enrolled 162 patients with a mean Charlson Comorbidity Index of 4.1 ± 2.2. Overall, 91 patients (56.2%) died. Antifungal susceptibility profiles were fluconazole (13/135, 9.6%), caspofungin (121/133, 91%), micafungin (125/126, 99.2%), anidulafungin (74/76, 97.4%), and amphotericin-B (50/134, 37.3%). Inadequate access to appropriate antifungals (odds ratio [OR] = 11.258; 90% confidence interval [CI]: 1.302-97.310; P = 0.065), the presence of central venous catheters (OR = 3.581; 90% CI: 1.037-12.368; P = 0.090), intensive care unit (ICU) stay (OR = 6.148; 90% CI: 1.977-19.123; P = 0.008), abdominal surgery (OR = 5.077; 90% CI: 1.651-15.610; P = 0.017), deep-seated candidal complications (OR = 4.546; 90% CI: 1.103-18.741; P = 0.079), and decreased platelet counts (OR = 1.004; 90% CI: 1.002-1.006; P = 0.006) were associated with increased mortality. Optimizing therapy for C. auris fungemia involves early strain identification, prompt echinocandin use, surveillance, proper catheter management, effective source control particularly in abdominal surgery, monitoring deep-seated candidal complications, and recognizing thrombocytopenia as a critical warning sign.
   
     
 
       

Author Related Publications

  • Fatma Abdelaziz Mossa, "Managing adult patients with infectious diseases in emergency departments: international ID-IRI study", Taylor& francis online, 2021 More
  • Fatma Abdelaziz Mossa, "Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: an international ID-IRI survey", springer, 2021 More
  • Fatma Abdelaziz Mossa, "Helicobacter pylori genotypes among patients in a university hospital in Egypt: identifying the determinants of disease severity", Journal of Microbiology and Infectious Diseases, 2013 More
  • Fatma Abdelaziz Mossa, "New targets for antibacterial agents", Biotechnol. Mol. Biol. Rev, 2008 More
  • Fatma Abdelaziz Mossa, "Bacteria of Nosocomial Urinary Tract Infections at a University Hospital in Egypt: Identification and Associated Risk Factors", The University of Chicago Press, 2004 More

Department Related Publications

  • Noha Mohamed El Sayed Hammad, "The incidence of Mycoplasma pneumoniae in community acquired pneumonia among children: one centre study", Microbes and Infectious diseases, 2020 More
  • Noha Mohamed El Sayed Hammad, "Complement component 3c and tumor necrosis factor-α systemic assessment after Candida antigen immunotherapy in cutaneous", Brazilian Journal of Microbiology, 2020 More
Tweet